Published in Women's Health Weekly, August 4th, 2005
According to InterGenetics, Oncovue has been developed as the first genetic-based breast cancer risk test relevant to all women. The agreement anticipates InterGenetics will purchase a minimum of $7.5 million in reagents from Tm over the 5-year period. The agreement is contingent on Tm delivering Tag-It reagents which perform according to InterGenetics' specifications.
Breast cancer is one of the most frequently diagnosed cancers among...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.